Vaxart (VXRT) Proxy filing summary

Executive summary

• Two new independent directors urge shareholders to vote for all six director nominees at the July 16, 2026 Annual Meeting, emphasizing the importance of continuity and experienced oversight.

• The Board is described as active, informed, and committed to holding management accountable, with frequent and substantive discussions focused on clinical progress, capital discipline, and long-term value.

• Recent actions include securing funding for a Phase 2b COVID-19 study, strengthening financials through partnerships, and streamlining operations in response to industry-wide challenges.

• The company is advancing a pipeline of oral recombinant vaccines, including candidates for coronavirus, norovirus, influenza, and HPV, supported by a proprietary delivery platform and broad patent applications.

• Forward-looking statements highlight expectations for clinical results, regulatory milestones, strategic partnerships, and capital resources, while cautioning about risks and uncertainties.

Voting matters and shareholder proposals

• Shareholders are urged to vote "FOR" all six director nominees on the WHITE proxy card to ensure experienced leadership and avoid disruption.

• A group of dissident shareholders seeks to replace half the Board, but current directors argue this would undermine progress and expertise.

Board of directors and corporate governance

• The Board includes recently appointed independent directors with extensive biotechnology and leadership experience.

• Directors at the center of the election bring critical life sciences, drug development, and regulatory expertise.

• Board discussions are described as frequent, substantive, and focused on accountability and strategic oversight.